Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-22
2011-03-22
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S233800, C514S321000, C514S365000, C514S375000, C544S062000, C544S133000, C544S143000, C546S198000, C548S202000, C548S217000
Reexamination Certificate
active
07910579
ABSTRACT:
It is intended to provide a benzoxazole derivative or a pharmaceutically acceptable salt or solvate thereof which is useful in the early diagnosis of a conformation disease; a composition or a kit containing the same for diagnosing a conformation disease; a medical composition for treating and/or preventing a conformation disease; and so on.
REFERENCES:
patent: 5374512 (1994-12-01), Heki et al.
patent: 2003/0003396 (2003-01-01), Berneth et al.
patent: 2003/0138374 (2003-07-01), Kudo et al.
patent: 2005/0009865 (2005-01-01), Kudo et al.
patent: 2005/0260126 (2005-11-01), Kudo et al.
patent: 2006/0018825 (2006-01-01), Kudo et al.
patent: 1 967 517 (2008-09-01), None
patent: 2000-344684 (2000-12-01), None
patent: 2000-344685 (2000-12-01), None
patent: 2002-275099 (2002-09-01), None
patent: 04 067659 (2004-03-01), None
patent: WO 96/34853 (1996-11-01), None
patent: WO 97 26919 (1997-07-01), None
patent: WO 98/47969 (1998-10-01), None
patent: WO 01/70699 (2001-09-01), None
patent: WO 02 080150 (2002-10-01), None
patent: WO 03/018070 (2003-03-01), None
patent: WO 03/106439 (2003-12-01), None
patent: WO 2005/016384 (2005-02-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta et al., abstract, Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Office Action in U.S. Appl. No. 12/097,842, mailed Feb. 22, 2010.
Morissette et al., “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids,” Advanced Drug Delivery Reviews, vol. 56, pp. 275-300 (2004).
Vippagunta et al., “Crystalline Solids,” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
International Search Report PCT/JP2007/063350 dated Aug. 7, 2007.
International Preliminary Report on Patentability; and Written Opinion of the International Searching Authority Application No. PCT/JP2007/063350 dated Jun. 30, 2009.
Koichi Ishiguro et al., “Phosphorylated Tau in Human Cerebrospinal Fluid is a Diagnostic Marker for Alzheimer's Disease”,Neuroscience Letters, 1999, pp. 91-94, vol. 270.
Nobuo Itoh et al., “Large-Scale, Multicenter Study of Cerebrospinal Fluid Tau Protein Phosphorylated at Serine 199 for the Antemortem Diagnosis of Alzheimer's Disease”,Ann. Neurol, 2001, pp. 150-156, vol. 50.
Claude M. Wischik et al., “Neurobiology of Alzheimer's Disease”, Oxford University, Press, 2001, pp. 103-206.
H. Braak et al., “Neuropathological Staging of Alzheimer-Related Changes”,Acta Neuropathol, 1991, pp. 239-259, vol. 82.
B. Yankner et al., “Neurotoxicity of a Fragment of the Amyloid Precursor Associated with Alzheimer's Disease”,Science, 1989, pp. 417-420, vol. 245.
H. Le Vine, “Thioflavine T Interaction with Synthetic Alzheimer's Disease {beta}-amyloid peptides: Detection of Amyloid Aggregation in Solution”,Protein Science, 1993, pp. 404-410, vol. 2.
H. Puchtler et al., “Application of Thiazole Dyes to Amyloid Under Conditions of Direct Cotton Dyeing: Correlation of Histochemical and Chemical Data”,Histochemistry, 1983, pp. 431-445, vol. 77.
Holde Puchtler et al., “On the Binding of Congo Red by Amyloid”,Journal of Histochemistry and Cytochemistry, 1961, pp. 355-364, vol. 10.
Ishikawa, K., et al., Styrylbenzoazole derivatives for imaging of prion plaques and treatment of transmissible spongiform encephalopathies, Journal of Neurochemistry, 2006, pp. 198-205, vol. 99.
Okamura, N., et al., Styrylbenzoxazole Derivatives for In Vivo Imaging of Amyloid Plaques in the Brain, The Journal of Neuroscience, Mar. 10, 2004, pp. 2535-2541, vol. 24.
Okamura, N., et al., Quinoline and Bezimidazole Derivatives: Candidate Probes In Vivo Imaging of Tau Pathology in Alzheimer's Disease, The Journal of Neuroscience., Nov. 23, 2005, pp. 10857-10862, vol. 25.
Shimadzu, H., et al., Novel probes for imaging amyloid-β:F-18 and C-11 labeling of 2-(4-aminostyryl) benzoxazole derivatives, Journal of Labelled Compounds and Radiopharmaceuticals, 2004, pp. 181-190, vol. 47.
Stetinova, J., et al.,2-(Benzoxazole-2-yl)-3-Heteroarylprop-2-enenitrile, Chem Papers, 1997, pp. 390-394, vol. 51 (6b) Compound IIc, IId.
International Search Report PCT/JP2006/325804 dated Mar. 20, 2007.
International Preliminary Report on Patentability; and Written Opinion of the International Searching Authority Application No. PCT/JP2006/325804 dated Jul. 1, 2008.
Extended European Search Report in European Application No. 07768120.3, issued Jun. 1, 2010.
Office Action in pending U.S. Appl. No. 12/097,842, mailed Aug. 18, 2010.
Furumoto Syozo
Kudo Yukitsuka
Okamura Nobuyuki
Chu Yong
Costellia Jeffrey L.
Nixon & Peabody LLP
Shterengarts Samantha L
Tohoku University
LandOfFree
Benzoxazole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoxazole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoxazole derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687334